153 related articles for article (PubMed ID: 38526757)
1. Utility of molecular markers in predicting local control specific to lung cancer spine metastases treated with stereotactic body radiotherapy.
Shor D; Louie AV; Zeng KL; Menjak IB; Atenafu EG; Chia-Lin Tseng ; Detsky J; Larouche J; Zhang B; Soliman H; Myrehaug S; Maralani P; Hwang DM; Sahgal A; Chen H
J Neurooncol; 2024 Apr; 167(2):275-283. PubMed ID: 38526757
[TBL] [Abstract][Full Text] [Related]
2. Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture.
Thibault I; Al-Omair A; Masucci GL; Masson-Côté L; Lochray F; Korol R; Cheng L; Xu W; Yee A; Fehlings MG; Bjarnason GA; Sahgal A
J Neurosurg Spine; 2014 Nov; 21(5):711-8. PubMed ID: 25170656
[TBL] [Abstract][Full Text] [Related]
3. Local control and patterns of failure for "Radioresistant" spinal metastases following stereotactic body radiotherapy compared to a "Radiosensitive" reference.
Zeng KL; Sahgal A; Husain ZA; Myrehaug S; Tseng CL; Detsky J; Sarfehnia A; Ruschin M; Campbell M; Foster M; Das S; Lipsman N; Bjarnason GA; Atenafu EG; Maralani PJ; Soliman H
J Neurooncol; 2021 Mar; 152(1):173-182. PubMed ID: 33453002
[TBL] [Abstract][Full Text] [Related]
4. Vertebral compression fracture risk after stereotactic body radiotherapy for spinal metastases.
Boehling NS; Grosshans DR; Allen PK; McAleer MF; Burton AW; Azeem S; Rhines LD; Chang EL
J Neurosurg Spine; 2012 Apr; 16(4):379-86. PubMed ID: 22225488
[TBL] [Abstract][Full Text] [Related]
5. Vertebral compression fractures after stereotactic body radiation therapy: a large, multi-institutional, multinational evaluation.
Jawad MS; Fahim DK; Gerszten PC; Flickinger JC; Sahgal A; Grills IS; Sheehan J; Kersh R; Shin J; Oh K; Mantel F; Guckenberger M;
J Neurosurg Spine; 2016 Jun; 24(6):928-36. PubMed ID: 26895526
[TBL] [Abstract][Full Text] [Related]
6. Mature Imaging-Based Outcomes Supporting Local Control for Complex Reirradiation Salvage Spine Stereotactic Body Radiotherapy.
Detsky JS; Nguyen TK; Lee Y; Atenafu E; Maralani P; Husain Z; Tseng CL; Myrehaug S; Soliman H; Sahgal A
Neurosurgery; 2020 Sep; 87(4):816-822. PubMed ID: 32374852
[TBL] [Abstract][Full Text] [Related]
7. Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy (SBRT): analysis of predictive factors.
Cunha MV; Al-Omair A; Atenafu EG; Masucci GL; Letourneau D; Korol R; Yu E; Howard P; Lochray F; da Costa LB; Fehlings MG; Sahgal A
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e343-9. PubMed ID: 22658511
[TBL] [Abstract][Full Text] [Related]
8. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.
Li Y; Jiang H; Qian F; Chen Y; Zhou W; Zhang Y; Lu J; Lou Y; Han B; Zhang W
Front Immunol; 2023; 14():1161718. PubMed ID: 37266427
[TBL] [Abstract][Full Text] [Related]
10. CT based quantitative measures of the stability of fractured metastatically involved vertebrae treated with spine stereotactic body radiotherapy.
Hardisty M; Wright T; Campbell M; Burke M; Atenafu E; Cawricz M; Caldwell C; Yee A; Sahgal A; Whyne C
Clin Exp Metastasis; 2020 Oct; 37(5):575-584. PubMed ID: 32643007
[TBL] [Abstract][Full Text] [Related]
11. Imaging-Based Outcomes for 24 Gy in 2 Daily Fractions for Patients with de Novo Spinal Metastases Treated With Spine Stereotactic Body Radiation Therapy (SBRT).
Tseng CL; Soliman H; Myrehaug S; Lee YK; Ruschin M; Atenafu EG; Campbell M; Maralani P; Yang V; Yee A; Sahgal A
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):499-507. PubMed ID: 30003994
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for vertebral compression fracture after spine stereotactic body radiation therapy: Long-term results of a prospective phase 2 study.
Mantel F; Sweeney RA; Klement RJ; Hawkins MA; Belderbos J; Ahmed M; Toussaint A; Polat B; Flentje M; Guckenberger M
Radiother Oncol; 2019 Dec; 141():62-66. PubMed ID: 31526672
[TBL] [Abstract][Full Text] [Related]
14. Normal tissue complication probability of vertebral compression fracture after stereotactic body radiotherapy for de novo spine metastasis.
Chen X; Gui C; Grimm J; Huang E; Kleinberg L; Lo L; Sciubba D; Khan M; Redmond KJ
Radiother Oncol; 2020 Sep; 150():142-149. PubMed ID: 32540335
[TBL] [Abstract][Full Text] [Related]
15. Vertebral Fractures Following Stereotactic Body Radiotherapy for Spine Oligometastases: A Multi-institutional Analysis of Patient Outcomes.
Abbouchie H; Chao M; Tacey M; Joon DL; Ho H; Guerrieri M; Ng M; Foroudi F
Clin Oncol (R Coll Radiol); 2020 Jul; 32(7):433-441. PubMed ID: 32169302
[TBL] [Abstract][Full Text] [Related]
16. Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis.
Lee E; Chen X; LeCompte MC; Kleinberg LR; Hales RK; Voong KR; Forde PM; Brahmer JR; Markowski MC; Lipson EJ; Lee SH; Bydon A; Lo SL; Lubelski D; Redmond KJ
J Neurosurg Spine; 2023 Aug; 39(2):278-286. PubMed ID: 37148233
[TBL] [Abstract][Full Text] [Related]
17. Dose-Escalated 2-Fraction Spine Stereotactic Body Radiation Therapy: 28 Gy Versus 24 Gy in 2 Daily Fractions.
Zeng KL; Abugarib A; Soliman H; Myrehaug S; Husain ZA; Detsky J; Ruschin M; Karotki A; Atenafu EG; Larouche J; Campbell M; Maralani P; Sahgal A; Tseng CL
Int J Radiat Oncol Biol Phys; 2023 Mar; 115(3):686-695. PubMed ID: 36309076
[TBL] [Abstract][Full Text] [Related]
18. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer.
Saw SPL; Ng WP; Zhou S; Lai GGY; Tan AC; Ang MK; Lim WT; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Chan JWK; Teh YL; Pang M; Yeo JC; Takano A; Ong BH; Tan EH; Tan SH; Skanderup AJ; Tan DSW
Eur J Cancer; 2023 Jan; 178():139-149. PubMed ID: 36436331
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
